Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Severe Asthma in the United States
| 대상 질환 | Asthma |
|---|---|
| 임상 단계 | 4상 |
| 스폰서 | AstraZeneca |
| 상태 | 완료 |
| 참여자 수 | 286 명 |
| 중재(약물) | Tezepelumab |
| 시작일 | 2022년 4월 29일 |
| 완료일 | 2025년 10월 1일 |
| 결과 공개일 | 2026년 7월 16일 |
요약
To asses effectiveness and safety of tezepelumab in adult and adolescent participants with severe asthma including several under-studied populations in the United States.
Annualized Asthma Exacerbation Rate (AAER)
| Tezepelumab | 2.8783 ± 2.69 Adjusted rate (exacerbations per year) |
|---|---|
| Tezepelumab | 0.8665 ± 0.71 Adjusted rate (exacerbations per year) |
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
- Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
- A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
- A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
- A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
- Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma — ARS Pharmaceuticals, Inc.